Craig S S, Irani A M, Metcalfe D D, Schwartz L B
Department of Anatomy, Medical College of Virginia, Virginia Commonwealth University, Richmond.
Lab Invest. 1993 Nov;69(5):552-61.
Mast cells derived from human skin and lung have been reported to produce heparin and chondroitin sulfate E proteoglycans. However, no information about the proteoglycans distribution among the different human mast cell types (MCTC and MCT) is available. Conjugates of antithrombin III-gold were used to assess the presence of heparin in both human mast cell subsets.
Thin sections of human and rodent tissues and dispersed cell preparations were labeled with the conjugate in the presence of saline, heparin, and chondroitin sulfates A and E and particle densities were measured over granules, perigranular regions, and extracellular space. Control sections were preincubated with heparinase, chondroitinase ABC, or buffer.
Labeling with antithrombin III-gold particles was detected in essentially all granules of human mast cells in skin (predominantly MCTC type), lung alveolar wall, and bowel mucosa (predominantly MCT type), but was negligible over human eosinophils. Consistent with the known distribution of heparin in rodent mast cells, strong labeling was observed over rat peritoneal connective tissue type mast cells, but not over mucosal mast cells in bowel mucosa of Nippostrongylus brasiliensis-infected rats (which contain chondroitin sulfate di-B) nor over mouse PT-18 mast cells (which contain chondroitin sulfate E). Mast cell labeling was preferentially blocked by exogenous heparin, and virtually abolished by heparinase but not chondroitinase ABC preincubation.
The data with rodent mast cells indicate that antithrombin III-gold labels cells that contain heparin, but not those that contain only over-sulfated chondroitin sulfates. Specificity of the procedure for detecting heparin is further demonstrated by inhibition of labeling after preincubation with heparinase and by competition with exogenous heparin. On this basis, we conclude that heparin is present in essentially all mast cells in normal skin, lung alveolar wall, and bowel mucosa. The presence of heparin in all human mast cells is different than for rodent mast cells, and probably accounts for the inability to clearly distinguish different human mast cell types from one another with histochemical stains based on proteoglycan content.
据报道,源自人皮肤和肺的肥大细胞可产生肝素和硫酸软骨素E蛋白聚糖。然而,关于不同人类肥大细胞类型(黏膜肥大细胞和结缔组织肥大细胞)中蛋白聚糖分布的信息尚不可得。抗凝血酶III-金复合物被用于评估两种人类肥大细胞亚群中肝素的存在情况。
人和啮齿动物组织的薄片以及分散的细胞制剂在生理盐水、肝素、硫酸软骨素A和E存在的情况下用该复合物进行标记,并测量颗粒、颗粒周围区域和细胞外空间的颗粒密度。对照切片用肝素酶、软骨素酶ABC或缓冲液进行预孵育。
在皮肤(主要是结缔组织肥大细胞类型)、肺泡壁和肠黏膜(主要是黏膜肥大细胞类型)中的人肥大细胞的基本上所有颗粒中均检测到抗凝血酶III-金颗粒标记,但在人嗜酸性粒细胞上可忽略不计。与肝素在啮齿动物肥大细胞中的已知分布一致,在大鼠腹膜结缔组织型肥大细胞上观察到强标记,但在巴西日圆线虫感染大鼠的肠黏膜中的黏膜肥大细胞(含有硫酸软骨素二B)或小鼠PT-18肥大细胞(含有硫酸软骨素E)上未观察到。肥大细胞标记优先被外源性肝素阻断,并且在肝素酶预孵育后几乎完全消除,但软骨素酶ABC预孵育则不会。
啮齿动物肥大细胞的数据表明,抗凝血酶III-金标记含有肝素的细胞,但不标记仅含有过度硫酸化硫酸软骨素的细胞。用肝素酶预孵育后标记的抑制以及与外源性肝素的竞争进一步证明了检测肝素方法的特异性。在此基础上,我们得出结论,正常皮肤、肺泡壁和肠黏膜中的基本上所有肥大细胞中都存在肝素。所有人类肥大细胞中肝素的存在情况与啮齿动物肥大细胞不同,这可能解释了基于蛋白聚糖含量的组织化学染色无法清楚区分不同人类肥大细胞类型的原因。